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Abstract
Symmetric dimethylarginine (SDMA) is a promising renal marker that correlates well with
the glomerular filtration rate and could allow earlier detection of impaired renal function. The
main objectives of this study were to assess the long-term variability of SDMA in healthy
dogs and examine the influence of an increased body fat percentage on the level of SDMA.
Sixteen lean Beagles were randomly assigned to the control group or weight-change group
in age- and gender-matched pairs. The energy intake of the control group (n = 8) was strictly
regulated to maintain an ideal body weight for 83 weeks, while the weight-change group (n =
8) was fed to induce weight gain (week 0–47), to maintain stable excessive body weight
(week 47–56) and to lose weight (week 56–83), consecutively. At 8 specified time points,
the body condition score, body composition, glomerular filtration rate, serum concentration
of SDMA and creatinine were analyzed. In the control group, the within-subject coefficient of
variation, between-subject coefficient of variation, reference change value (type I error =
5%) and index of individuality were 0.16, 0.22, 0.43 and 0.73, respectively. The control
group and weight-change group did not differ significantly in SDMA concentration. SDMA
showed a significant negative association (coefficient = -0.07) with body fat percentage
(p<0.01) in the weight-change group and a significant positive association (coefficient =
7.79) with serum creatinine (p<0.01) in the entire study population. In conclusion, SDMA
concentration has high long-term stability in healthy adult dogs. For the evaluation of SDMA
concentrations, subject-specific reference values are preferred over a population-based ref-
erence value seen their higher sensitivity. Moreover, an increased body fat percentage does
seem to affect the serum SDMA concentration of otherwise healthy dogs, but its clinical rele-
vance has to be clarified in further research.
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Introduction
Symmetric dimethylarginine (SDMA) is a promising renal marker and has been proposed as
an alternative to glomerular filtration rate (GFR) [1]. SDMA is released into circulation by
eukaryotic cells following proteolysis and is mainly excreted by the kidney (�90%) [2–5].
Studies in various species, such as humans, dogs and cats, have shown a good correlation
between SDMA and GFR, and have demonstrated that SDMA provides added value in the
detection and monitoring of impaired renal function [6–9]. SDMA is highly reliable as the
number of confounding factors is limited [6, 10–12]. Unlike serum creatinine (sCr), SDMA is
not influenced by age in adult dogs, lean body mass or gender [10–13]. Furthermore, SDMA
might have advantages for the early detection of impaired renal function as 35 to 50% less
nephron mass must be lost to cause a significant increase compared to sCr [6, 8, 9, 11, 13, 14].
To enable interpretation of SDMA results, a population-based reference-interval (6–13 μg/
dl) and reference limit (<14 μg/dl) have been established based on healthy adult dogs [6, 15,
16]. However, data on SDMA variability, within and between healthy dogs, is necessary to
assess the sensitivity of the population-based reference-interval to detect pathological changes
in an individual over time [17, 18]. Nevertheless, this data is scarce and only known for rela-
tively short periods [19]. Previously, Kopke et al. performed a variability study of two and a
half months [19]. The researchers found a within-subject coefficient of variation (CVI) of 14%
for SDMA, suggesting that the concentration remains consistent within this short timeframe
[19].
So far, the influence of lean body mass on SDMA has been evaluated [9–11], while little
data is available on the effect of obesity on the serum SDMA concentration in dogs. However,
up to 20% of the canine population is affected by obesity, a chronic disease associated with
excessive body fat accumulation [20–23]. In addition, data suggest that obesity might affect
renal structure and function in both humans and dogs [24–29]. Experimental canine studies
reported histological, hemodynamic and functional changes of the kidney during early weight-
gain, including e.g. glomerular hypertrophy, increased mesangial matrix and thickening of glo-
merular and tubular basement membranes [27, 28]. Over time, chronic obesity may lead to
progressive renal damage and development of chronic kidney disease [27–29]. Therefore, the
renal function of obese dogs should be closely monitored [27–30]. Given the promising results,
SDMA could play an important role in the follow-up of obese patients provided that the
SDMA concentration is not affected by body fat percentage (BF%). In humans, studies show
contradictory results on the effect of obesity on SDMA concentration [31–35].
The aims of this study were to assess the variability of SDMA in healthy dogs with stable
kidney function over a longer period and to examine whether an increased BF% has an influ-
ence on the level of SDMA.
Materials and methods
For this study, samples from a previously published longitudinal study of 1.5 years evaluating
the effect of weight change on canine kidney function were used. For a detailed description of
the study design and additional results, reference is made to the article by Liu et al. [27].
Animals
This study included sixteen lean, purpose-bred research Beagles (eight male [four neutered]
and eight female [two spayed]). At the start, the dogs were between 2.7 and 8.5 years old
(mean ± standard deviation (SD), 4.4 ± 2.0 years), had a mean body weight (BW) of 11.4 kg
(SD = 1.8 kg) and ideal body condition score (BCS) of 4-5/9 (mean ± SD, 4.1 ± 0.25) according
to the 9-point scale of Laflamme [36]. All dogs were declared healthy based on a physical
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examination, comprehensive urinalysis and blood analysis. The Beagles were housed in con-
trolled kennel conditions in accordance with European and national regulations for the care
and use of animals at the Faculty of Veterinary Medicine (University of Ghent, Belgium). The
study was approved by the Local Animal Ethics Committee of the Faculties of Veterinary Med-
icine and Bioscience Engineering, Ghent University (Project Number: EC2016/92). Following
this research, the animals were housed for use in further studies.
Experimental design
In the first four weeks of the study, the dogs were adapted to a commercially available adult
maintenance dry diet (Veterinary™ HPM Adult Large and Medium, Virbac, Carros, France).
Subsequently, the dogs were randomly assigned to the control group (CG) (n = 8) or weight-
change group (WCG) (n = 8) in matched pairs based on age and gender.
For the dogs in the CG, their energy intake was strictly regulated to maintain an ideal BW
(mean ± SD, 12.1 ± 1.7 kg) and BCS (mean ± SD, 4.1 ± 0.3) in all individuals for 83 weeks. The
dogs in the WCG followed three consecutive phases, namely a weight gain phase (week 0–47),
a weight stable phase (week 47–56) and weight-loss phase (week 56–83). The weight gain
phase aimed to induce excessive BW or obesity, the weight stable phase aimed to maintain sta-
ble excessive BW, while the aim of the final phase was to return to the BW and BCS from the
start of the study. The weight changes were induced by adjusting the energy intake by chang-
ing the amount of food from the same commercial diet.
Sample collection was performed at eight time points and started at week 0, 12, 24, 36, 47,
56, 68 and 83, respectively. For practical reasons, sampling was conducted over two weeks. On
the second day of the first week, blood samples (12ml) were collected after a 12h fast and GFR
was determined by plasma clearance of exo-iohexol. On the third day of the second week,
morning urine samples in unsedated patients were collected by ultrasound-guided cystocent-
esis (22G needle). On the last day of the second week, body composition was determined by
the deuterium oxide dilution method [37, 38]. An exception was made at week 68, when the
measurements were performed within one week and were limited to blood sample collection
and cystocentesis. At week 0, 24, 47, 56 and 83, a complete blood count and serum biochemis-
try profile (Architect C16000, Abbott Max-PlanckRing, Wiesbaden, Germany) were per-
formed on all Beagles.
Procedures
Body condition score and body composition. Based on visual inspection and palpation a
BCS was assigned using a 9-grade scale [36]. Body composition was determined by the deute-
rium oxide dilution method using Fourier-transform infrared spectroscopy, as described by
Ferrier et al. [37, 38]. Briefly, a blood sample was drawn from the jugular vein and collected in
an EDTA tube after a 2h fast (water and food), followed by a subcutaneous injection of deute-
rium (500 mg/kg). Four hours post-injection, a second sample was collected. These blood sam-
ples were spun at 2000 x g for 5 minutes at a temperature of 21˚C as soon as possible. The
plasma was stored in 300 μL Eppendorf tubes at -20˚C, until further analysis of the deuterium
concentration as described by Ferrier et al. [37].
Glomerular filtration rate. Clearance of exo-iohexol was used to estimate GFR, as previ-
ously described [39–41]. Briefly, blood was sampled from the jugular vein after 12-hour food
deprivation, followed by an intravenous dose of iohexol (64.7 mg/kg BW, Omnipaque 3001,
GE Healthcare, Diegem, Belgium). Post-injection, multiple blood samples were collected on
pre-specified time points. Immediately after blood collection, the samples were centrifuged
and the plasma was frozen in Eppendorf tubes at -20˚C until assayed. The exo-iohexol
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concentration was measured by high-performance liquid chromatography (HPLC) [39, 41],
after which a non-compartmental analysis (Phoenix 6.4, Princeton, NJ, USA) was performed
to determine exo-iohexol clearance [41].
Laboratory variables. Serum SDMA concentrations were measured with a commercially
available, novel, high-throughput, competitive homogeneous immunoassay (IDEXX SDMA1
Test, IDEXX Laboratories, Inc. Westbrook, ME 04092, United States) using a glucose-6-phos-
phate dehydrogenase conjugate and anti-SDMA monoclonal antibody [42].
As part of the serum biochemistry profile, sCr was determined by an automated chemistry
analyzer (Architect C16000, Abbott Max-Planck-Ring, Wiesbaden, Germany). Concentrations
lower than 1.4 mg/dl (123.76 μmol/l) were considered normal [43].
Statistical analyses
The statistical analysis was conducted in R version 3.4.4. Significance was set at α� 0.05. A
random-effects model using restricted maximum likelihood (lme4 package) was used to esti-
mate the variance components within the CG. Two variance components were estimated, v1
represents the variation between repeated measurements on the dog and v2 represents the
extra variation when considering observations of different dogs. The variance components
were used to determine 95% reference intervals for repeated observations in the same dog and
for repeated observations in different dogs. The coefficient of variation (CV), defined as the
ratio of the standard deviation over the mean, was determined for the within-dog repeated
observations (CVI) and between-dog repeated observations (CVG). Furthermore, the reference
change value (RCV) at a 5% confidence level and the index of individuality (IOI) were deter-
mined according to the ASVCP reference interval guidelines [44].
Next, the effect of changes in BF% on SDMA levels was analyzed in the WCG using a linear
mixed model with dog as a random effect. Finally, in the total data set, four separate linear
mixed models were used to evaluate whether the interaction between group (case/control) and
time point was significant; SDMA, GFR, sCr or BF% were defined as dependent variables,
group, time point and the interaction were defined as fixed effects, and dog was defined as a
random effect. The association between SDMA (dependent variable) and GFR or sCr (fixed
effect) was also assessed with a linear mixed model with dog as a random effect.
Results
Results concerning BW, BCS and BF% were previously published by Liu et al. [27]. Briefly, the
BF%, BW and BCS were significantly higher in the WCG from week 12 or 24 to week 56. At
the end of the weight gain phase (week 47), three dogs of the WCG were overweight and five
were obese.
Throughout the study, the serum SDMA concentration of all dogs remained below the
upper reference limit (14 μg/dl). The lower reference limit of 6 μg/dl was crossed multiple
times in both groups, with a minimal concentration of 4 μg/dl. In the CG, a 95% confidence
interval within dogs (5.3–10.2 μg/dl) with a variance of 1.54, and a 95% confidence interval
between dogs (4.3–11.2 μg/dl) with an added variance of 1.38 were established. The intercept
(mean), standard error, CVG and CVI of SDMA in the CG were 7.76, 0.47, 0.22 and 0.16,
respectively. Furthermore, an IOI of 0.73 and a RCV of 0.43 were calculated for SDMA. No
significant difference was found over time between the CG and WCG. The results of the
SDMA measurements over time are reported for both groups in Table 1. The course of the
SDMA concentration for the CG and WCG during the weight-gain phase, weight-stable phase
and weight-loss phase is visually represented in Fig 1.
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Results concerning sCr and GFR were also previously published by Liu et al. [27]. Briefly,
sCr concentrations were within the laboratory reference interval for all dogs and was not sig-
nificantly different between the CG and WCG over time. Similarly, no significant difference
was detected for GFR between both groups. The profile of GFR from the two groups were par-
allel to each other, with slightly higher values in the CG. For both groups, a slight decrease
could be observed until week 36. Afterwards, GFR of both groups showed a gradual increase
until the end of the study.
Table 1. SDMA concentration (μg/dl) of the dogs in the Control Group (CG)a and Weight-Change Group (WCG) over time.
Week 0 12 24 36 47 56 68 83
CG Mean 8.86 8.14 7.43 8.0 7.71 8.0 7.88 7.88
SD 2.0 1.7 2.2 0.8 1.1 2.2 2.0 1.1
WCG Mean 8.0 7.0 6.88 6.88 7.0 6.5 8.0 7.5
SD 0.9 1.4 1.0 1.8 1.5 1.1 2.1 2.1
The mean concentration and standard deviation (SD) at all measured time points are presented per group (n = 8). With dietary management, the control group was
kept at an ideal body weight throughout the study (week 0–83). In the weight-change group, dietary adjustments were made to induce excessive weight gain (week
0–47), to maintain body weight (week 47–56) and to induce weight-loss (week 56–83), successively. aData from 1 dog missing. SDMA, symmetric dimethylarginine.
https://doi.org/10.1371/journal.pone.0247049.t001
Fig 1. Serum SDMA concentration of the dogs in the control group (closed circles, n = 8)a and weight-change
group (open circles, n = 8) throughout the study. The weight-change group underwent three consecutive phases,
namely the weight gain phase (week 0–47), weight-stable phase (week 47–56) and weight-loss phase (week 56–83). The
subjects from the control group were kept at an ideal body weight. aData from 1 dog missing. SDMA, symmetric
dimethylarginine.
https://doi.org/10.1371/journal.pone.0247049.g001
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A significant association was found between SDMA and BF% (coefficient = -0.07, p<0.01)
in the WCG and between SDMA and sCr (coefficient = 7.79, p<0.01) in the entire study popu-
lation, respectively. SDMA and BF% are negatively associated, i.e., if the fat percentage
increases by 1%, the SDMA concentration decreases by 0.07 μg/dl. In contrast, SDMA and sCr
are positively associated, i.e., if sCr increases by 1 mg/dl, the SDMA concentration increases by
7.79 μg/dl. No significant association was found between SDMA and GFR. The association of
BF% and sCr with SDMA is shown in Fig 2.
One of the control dogs was diagnosed with multicentric lymphoma in week 60 and was
euthanized. The data from this dog were not included in the statistical analysis.
Discussion
SDMA is a renal marker with growing importance in the early detection of renal dysfunction
in dogs [1, 6–9]. Data on the variability of SDMA is necessary to assess the sensitivity of the
population-based reference-interval in the detection of impaired renal function [17, 18]. More-
over, the renal function of obese dogs should be closely monitored, because of their increased
risk on histological, hemodynamic and functional changes in the kidney [27–29]. However,
prior research in dogs studied only the short-term variability of SDMA [19] and little data is
available on the effect of obesity on the serum SDMA concentration in dogs, while a significant
proportion of the pet dog population is overweight [20–22, 45, 46]. Therefore, the main objec-
tives of this study were to assess the long-term variability of SDMA in healthy dogs and exam-
ine the influence of an increased BF% on the level of SDMA. In this long-term study of 1.5
years, SDMA showed a relatively high long-term stability in healthy adult dogs with an inter-
mediate IOI. Moreover, a significant negative association was observed between SDMA and
BF% in dogs with an excessive BW.
The within-subject coefficient of variation (CVI) indicates the extent to which serial mea-
surements fluctuate within the same subject [47]. Knowledge of the variation of an analyte is
essential as it can influence the interpretation of results [48]. This study found a relatively low
Fig 2. The association of SDMA with body fat percentage (A) and serum creatinine (sCr) (B) in dogs. SDMA showed a significant negative association (coefficient =
-0.07) with body fat percentage (p<0.01) in the weight change group and a significant positive association (coefficient = 7.79) with serum creatinine (sCr) (p<0.01) in the
entire study populationa. aData from 1 dog missing in the control group. SDMA, symmetric dimethylarginine.
https://doi.org/10.1371/journal.pone.0247049.g002
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long-term variability for SDMA, indicating that canine serum SDMA concentration is rela-
tively consistent over long periods and that mild changes in serial measurements might be sig-
nificant. Therefore, subject-specific reference values might be more sensitive in assessing
relevant changes in SDMA than the population-based reference interval [49, 50]. Liu et al. pre-
viously studied the long-term within-dog variability of sCysC, uRBP, uNGAL, uIgG, and
uCRP [51]. Compared to these renal biomarkers, except for sCysC (CVI 8.1%), SDMA shows
the lowest CVI.
Kopke et al. reported a similar CVI of 14% for SDMA in a 10-week long study with an aver-
age sample interval of 8 days (range, 2–14 days) [19]. In contrast, the current study lasted
more than 80 weeks, with an average sample interval of 12 weeks (range, 9–15 weeks). From
these two studies, the sample interval appears to have a limited impact on the variation of
SDMA. However, in general, a longer time interval between sample collection is thought to
result in higher analytical and biological variability [49]. The minimal difference in CVI
between both studies is probably attributable to a small increase in biological variation over
time as both studies applied the same assay and minimalized analytical variance by batch anal-
yses of the samples at the end of the study. However, a substantial proportion of the within-
subject variability is probably caused by the analytical error of the applied assay as a consider-
ably high analytical variability ranging from 7.7% to 10% has been reported for the IDEXX
SDMA test [19, 52, 53].
To determine whether the subject-specific reference values are preferable to a population-
based reference interval, IOI can be used [49, 50]. When an analyte has a high individuality,
i.e., low IOI (<0.6), subject-specific reference values are preferred as a measurement might fall
within the population-based RI but is significantly different from an individual’s homeostatic
set point [49, 54, 55]. When the IOI is larger than 1.4, subject-specific reference values add no
additional information compared to a population-based RI and are no longer the method of
first choice [49, 54, 55]. The intermediate IOI found in this study indicates that the popula-
tion-based reference value may be used, but with caution as the population-based reference
interval has limited sensitivity in this situation [49, 55]. Generally, the application of subject-
specific reference values is often also recommended with an intermediate IOI [19]. The two
main subject-specific reference values used for analyte evaluation are RCV and subject-based
reference interval [49]. RCV refers to the percentage change that is minimally required to con-
sider the difference between two consecutive results of an individual significant [56–58]. A
subject-based reference interval, on the other hand, is a range of values that has been estab-
lished based on measurements from one individual and is only applied to this same individual
to evaluate subsequent results [49]. The RCV found in this study indicates that a difference of
more than 43% between two consecutive SDMA measurements would be significant and can-
not be ascribed to natural variation [18]. Previously, Kopke et al. found a similar IOI and RCV
for SDMA of 0.87 and 47%, respectively [19]. A disadvantage of subject-specific reference val-
ues is that to be able to detect pathological changes, an individual’s normal value, based on
serial measurements in an individual that is still healthy, has to be established first [19, 49].
Up to now, no major extra-renal influences on serum SDMA have been identified [6, 59].
However, the potential importance of SDMA as a diagnostic tool was only discovered recently,
and the influence of many factors, such as obesity, is not yet well known [1, 60, 61]. Obesity is
a pathology that might influence the variation around the set-point of SDMA or the set-point
itself so that the evaluation of results using reference values based on healthy individuals could
lead to misinterpretation [49, 62, 63]. A separate reference interval might be needed for obese
dogs, as studies suggest that this group has a higher risk of developing renal dysfunction, and
therefore monitoring these animals could be crucial [24–29]. In this study, SDMA was signifi-
cantly associated with BF% in the WCG, indicating that there is a significant effect of increased
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BF% on the serum concentration of SDMA. However, no significant difference between the
WCG and CG was found for SDMA despite a significantly higher BF%. Therefore, the clinical
relevance of the negative association found between SDMA and BF% is unclear. The lack of a
significant difference in SDMA concentration between both groups may be due to insufficient
weight gain in the WCG or due to the limited power of this study to detect a significant differ-
ence. To exclude the latter, however, it needs to be determined which difference is considered
clinically relevant. Further research needs to clarify whether an adjusted reference interval for
obese dogs has to be established. In humans, various studies explored the relationship between
SDMA and obesity [31–35]. However, their results are contradictory showing either no [34], a
positive [31, 33], or a negative effect [32, 35] of obesity on SDMA.
The negative association found between SDMA and BF% contradicts the initial expectation.
However, this result is in line with two studies in humans that reported a significantly lower
SDMA concentration in juvenile and adult obese patients [32, 35]. The exact cause of this neg-
ative relationship is not clear, but researchers have proposed several theories that could be
directly or indirectly linked with obesity [32, 64]. The first theory is that the negative associa-
tion is the result of increased glomerular filtration and more efficient secretion of SDMA [32,
64]. Nevertheless, there were no direct indications of an enhanced renal function in studies
that demonstrated a lower SDMA level in obese subjects [32, 35]. Previous studies do show,
however, that obese individuals might be in a pre-diabetic or diabetic state associated with glo-
merular hyperfiltration which might result in the increased renal elimination of SDMA [65–
67]. In this study, GFR was not significantly different between both groups and even showed a
negative association with BF%. Two alternative theories that have been proposed for the nega-
tive relationship between SDMA and BW are increased cellular uptake and increased hepatic
extraction of SDMA. Both mechanisms have been linked to elevated insulin levels associated
with obesity-induced insulin resistance [64, 68].
To our knowledge, this study was the first to evaluate the long-term variability of serum
SDMA in healthy dogs and to explore the effect of an increased BF% on the SDMA concentra-
tion while closely monitoring renal function by GFR. By including GFR measurements in the
study design, possible changes in the SDMA concentration caused by renal dysfunction were
excluded. Also, other potential sources of variability were kept to a minimum by the study
design. Specifically, all laboratory dogs belonged to the same breed and were randomly divided
into CG and WCG by age- and gender-matched pairs. They were all housed in a strictly con-
trolled environment, received food with the same dietary composition, and samples were
taken according to a predetermined protocol. Despite these strengths, the present study also
had some limitations. The first limitation is the low number of subjects included in the study.
As a result, a significant difference might not have been noticed. However, pre-analytical and
analytical variations were minimized to avoid possible confounding factors that are not of
interest and should allow the assessment of biological variation even with a low number of
individuals [49, 55]. Complete elimination of the analytical variance was not possible, though,
due to the difference in storage length between the first and last collected samples. The second
limitation is the relatively high analytical variability of the applied SDMA assay, which has
been reported to be between 7.7% and 10% [19, 52, 53]. According to published guidelines, the
CVA of an analytical method should be<0.5 CVI to have a desirable performance [69]. In this
study the CVA fluctuates around the maximum acceptable value. Therefore, a potentially sig-
nificant portion of the variance may be due to analytical imprecision. Future studies should
include an extended study population of obese dogs and determine, in addition to SDMA,
body composition, insulin level, insulin resistance and renal glomerular filtration rate.
In conclusion, SDMA concentrations in healthy adult dogs have relatively high long-term
stability. Furthermore, extended sampling intervals seem to be associated with a minimal
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increase in biological variation. For the evaluation of SDMA concentrations, subject-specific
reference values are preferred over a population-based reference value because of their higher
sensitivity. Moreover, increased BF% does seem to affect the serum SDMA concentration of
otherwise healthy dogs, but its clinical relevance has to be clarified in further research.
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3. Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E, et al. Marked increase of asym-
metric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol.
2002; 13(1):170–176. PMID: 11752034
4. Ogawa T, Kimoto M, Watanabe H, Sasaoka K. Metabolism of NG, NG—and NG, N’G -dimethylarginine
in rats. Arch Biochem Biophys. 1987; 252(2):526–537. https://doi.org/10.1016/0003-9861(87)90060-9
PMID: 3101600
PLOS ONE Long-term variability of serum symmetric dimethylarginine in dogs and the effect of body fat percentage
PLOS ONE | https://doi.org/10.1371/journal.pone.0247049 February 17, 2021 9 / 13
5. McDermott JR. Studies on the Catabolism of NG- Methylarginine, NG,N’G- Dimethylarginine and NG,NG-
Dimethylarginine in the Rabbit. Biochem J. 1976; 154(1):179–184. https://doi.org/10.1042/bj1540179
PMID: 1275907
6. Nabity MB, Lees GE, Boggess MM, Yerramilli M, Obare E, Yerramilli M, et al. Symmetric dimethylargi-
nine assay validation, stability, and evaluation as a marker for the early detection of chronic kidney dis-
ease in dogs. J Vet Intern Med. 2015; 29(4):1036–1044. https://doi.org/10.1111/jvim.12835 PMID:
26079532
7. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA)
as endogenous marker of renal function—A meta-analysis. Nephrol Dial Transplant. 2006; 21(9):2446–
2451. https://doi.org/10.1093/ndt/gfl292 PMID: 16766542
8. Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell DE. Serum Concentrations of Symmetric
Dimethylarginine and Creatinine in Dogs with Naturally Occurring Chronic Kidney Disease. J Vet Intern
Med. 2016; 30(3):794–802. https://doi.org/10.1111/jvim.13942 PMID: 27103204
9. Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE. Comparison of Serum Concentrations of Sym-
metric Dimethylarginine and Creatinine as Kidney Function Biomarkers in Cats with Chronic Kidney Dis-
ease. J Vet Intern Med. 2014; 28:1676–83. https://doi.org/10.1111/jvim.12445 PMID: 25231385
10. Pedersen LG, Tarnow I, Olsen LH, Teerlink T, Pedersen HD. Body size, but neither age nor asymptom-
atic mitral regurgitation, influences plasma concentrations of dimethylarginines in dogs. Res Vet Sci.
2006; 80(3):336–342. https://doi.org/10.1016/j.rvsc.2005.07.005 PMID: 16182327
11. Hall JA, Yerramilli M, Obare E, Yerramilli M, Melendez LD, Jewell DE. Relationship between lean body
mass and serum renal biomarkers in healthy dogs. J Vet Intern Med. 2015; 29(3):808–814. https://doi.
org/10.1111/jvim.12607 PMID: 25913398
12. Moesgaard SG, Holte A V., Mogensen T, Mølbak J, Kristensen AT, Jensen AL, et al. Effects of breed,
gender, exercise and white-coat effect on markers of endothelial function in dogs. Res Vet Sci. 2007; 82
(3):409–415. https://doi.org/10.1016/j.rvsc.2006.09.003 PMID: 17092526
13. Braun JP, Lefebvre HP, Watson ADJ. Creatinine in the Dog: A Review. Vet Clin Pathol. 2003; 32
(4):162–179. https://doi.org/10.1111/j.1939-165x.2003.tb00332.x PMID: 14655101
14. Pressler BM. Clinical Approach to Advanced Renal Function Testing in Dogs and Cats. Vet Clin North
Am Small Anim Pract. 2013; 43(6):1193–1208. https://doi.org/10.1016/j.cvsm.2013.07.011 PMID:
24144085
15. Rentko V, Nabity M, Yerramilli M. Determination of serum symmetric dimethylarginine reference limit in
clinically healthy dogs [abstract]. J Vet Intern Med. 2013; 27:750.
16. Hokamp JA, Nabity MB. Renal biomarkers in domestic species. Vet Clin Pathol. 2016; 45(1):28–56.
https://doi.org/10.1111/vcp.12333 PMID: 26918420
17. Kjelgaard-Hansen M, Jensen LA. Reference Intervals. In: Weiss DJ, Wardrop KJ, Weiss D, editors.
Schalm’s Veterinary Hematology. 6th ed. Hoboken, New Jersey: John Wiley & Sons; 2010. pp. 1034–
1038.
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